MacroGenics Inc. (MGNX)
NASDAQ: MGNX
· Real-Time Price · USD
1.63
-0.09 (-5.23%)
At close: Sep 11, 2025, 2:27 PM
MacroGenics Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing Revenue | 15.37M | 6.15M | 3.31M | 4.57M | 2.89M | 2.28M | 169K | 4.46M | 1.59M | 3.62M | 8.85M | 1.14M | 3.99M | 7.09M | 11.99M | 27.17M | 15.18M | 17.41M | 15.64M |
| Contract Manufacturing Revenue Growth | +149.95% | +85.52% | -27.51% | +58.07% | +27.11% | +1246.75% | -96.21% | +181.16% | -56.10% | -59.17% | +675.31% | -71.39% | -43.72% | -40.82% | -55.88% | +78.93% | -12.81% | +11.38% | n/a |
| RevenueFromCollaborativeAgreementsMember Revenue | 6.87M | 7.04M | n/a | 101.41M | 2.06M | 1.45M | n/a | 885K | 6.02M | 16.69M | n/a | 35.67M | 16.86M | n/a | n/a | n/a | n/a | n/a | n/a |
| RevenueFromCollaborativeAgreementsMember Revenue Growth | -2.46% | n/a | n/a | +4810.80% | +42.51% | n/a | n/a | -85.30% | -63.92% | n/a | n/a | +111.55% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 9.3M | 10.72M | 27.81M | 14.1M | 14.42M | 14.71M | 12.56M | 12.41M | 13.69M | 13.53M | 13.67M | 15.36M | 13.67M | 16.25M | 15.58M | 17.16M | 15.23M | 15.04M | 12.56M | 9.73M | 10.22M | 10.23M | 11.89M | 11.83M | 12.12M | 10.22M | 10.55M | 9.58M | 11.13M | 9.23M | 8.4M | 8.4M | 8.38M | 7.46M | 9.23M | 7.22M | 7.24M | 6.13M | 6.71M | 6.02M | 5.35M | 4.68M |
| Selling, General, and Administrative Revenue Growth | -13.21% | -61.46% | +97.18% | -2.21% | -1.94% | +17.11% | +1.22% | -9.37% | +1.22% | -1.06% | -10.96% | +12.33% | -15.90% | +4.30% | -9.20% | +12.65% | +1.32% | +19.70% | +29.07% | -4.74% | -0.17% | -13.94% | +0.48% | -2.38% | +18.62% | -3.11% | +10.05% | -13.92% | +20.56% | +9.89% | +0.01% | +0.23% | +12.36% | -19.20% | +27.84% | -0.21% | +18.03% | -8.67% | +11.53% | +12.63% | +14.16% | n/a |
| Research and Development Revenue | 40.79M | 39.7M | 38.89M | 40.54M | 51.73M | 46.03M | 45.45M | 30.13M | 43.23M | 45.87M | 45.65M | 48.19M | 51.74M | 61.44M | 55.85M | 49.82M | 55.78M | 53.12M | 42.3M | 44.66M | 57.35M | 48.89M | 51.96M | 44.85M | 51.44M | 47.06M | 46.92M | 46.22M | 52.01M | 45.67M | 38.99M | 40.98M | 34.46M | 32.8M | 31.11M | 30.3M | 33.34M | 27.35M | 30.04M | 24.1M | 22.66M | 21.46M |
| Research and Development Revenue Growth | +2.75% | +2.08% | -4.08% | -21.63% | +12.39% | +1.27% | +50.84% | -30.30% | -5.76% | +0.48% | -5.27% | -6.87% | -15.78% | +10.00% | +12.10% | -10.68% | +5.01% | +25.58% | -5.28% | -22.14% | +17.30% | -5.90% | +15.84% | -12.81% | +9.31% | +0.29% | +1.53% | -11.14% | +13.89% | +17.14% | -4.88% | +18.93% | +5.06% | +5.44% | +2.68% | -9.13% | +21.92% | -8.98% | +24.65% | +6.37% | +5.57% | n/a |